Skip to main content
S&P 5007,666.45+0.19%DOW50,926.56+0.04%NASDAQ26,871.60+0.04%BTC$84,617.00+1.19%ETH$2,698.31+0.66%GOLD$4,207.90+0.51%OIL$92.92+2.76%
Smart Investors Daily
SID Premium
IL

NASDAQ · ILMN

Illumina, Inc.

Healthcare · Medical - Diagnostics & Research

$273.68

Down-$7.96 (-2.91%)

Updated Oct 1, 2026, 8:25 PM

SID Score

6.7/10

Composite research score

Smart Money

58/100

Neutral

Market cap
20.84B
P/E ratio
30.27
Dividend yield
0.00%
52-week range
$88.00 – $278.99
Volume
2.94M
Avg. volume
1.79M

Price performance · ILMN

ILMN price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Sep 30, 2026

ILMN closed at $273.68 after 20 trading sessions, up 28.34% for the selected period.

Last close
$273.68
Period change
+28.34%
Period low
$201.27
Period high
$273.90
Daily close
View OHLC price history
ILMN OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 30, 2026$272.71$280.165$270.295$273.682.94M
Sep 29, 2026$273.10$278.99$267.00$272.002.23M
Sep 28, 2026$265.95$275.6907$262.89$271.902.98M
Sep 25, 2026$272.16$276.97$267.66$270.005.03M
Sep 24, 2026$253.79$277.95$250.918$273.903.48M
Sep 23, 2026$248.79$256.17$246.995$255.382.3M
Sep 22, 2026$237.09$248.1575$234.57$247.462.64M
Sep 21, 2026$241.505$248.3099$238.26$238.823.19M
Sep 18, 2026$249.13$250.06$236.42$239.6232.59M
Sep 17, 2026$233.85$246.76$232.99$245.183.68M
Sep 16, 2026$224.49$236.00$223.70$228.933.38M
Sep 15, 2026$208.95$226.76$207.895$222.293.15M
Sep 14, 2026$206.74$208.93$202.815$208.212.06M
Sep 11, 2026$201.81$208.39$200.01$206.452.41M
Sep 10, 2026$203.69$206.07$200.56$201.271.29M
Sep 9, 2026$211.625$212.18$203.6048$205.001.71M
Sep 8, 2026$218.65$219.45$210.15$211.061.82M
Sep 4, 2026$216.74$219.575$213.95$218.221.75M
Sep 3, 2026$213.24$221.76$210.94$221.661.72M
Sep 2, 2026$208.62$214.98$207.13$213.251.77M

Latest ILMN news

The latest Smart Investors Daily articles mentioning ILMN.

Stock researchCompany · Overview

ILMN research

Overview

Company profile and research snapshot.

Company profile

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Hold
Average target
$115.25
Implied upside
—
Analysts
28
ILMN recent ratings
DateFirmRatingTarget
Oct 1, 2026GuggenheimBuy—
Sep 29, 2026Leerink PartnersOutperform—
Sep 28, 2026Piper SandlerOverweight—
Sep 9, 2026UBSBuy—
Sep 3, 2026Argus ResearchBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 25, 2026

Illumina (ILMN) Tests Valuation As Russell Index Removal Forces A Fresh Look

Index removal puts Illumina in focus Illumina (ILMN) has been removed from the Russell Small Cap Value Index, an index reshuffle that can prompt mechanical selling and raise fresh questions about how the stock is being valued today. The index removal comes at a time when Illumina’s momentum is already strong, with a 1-day share price return of 7.25%, a 30-day share price return of 21.82% and a year-to-date share price return of 103.87%. These feed into a 1-year total shareholder return of...

Yahoo · Sep 22, 2026

NICU Genetic Testing Market Size, Share & Trends Analysis - Global Opportunity Analysis and Industry Forecast (2026-2036)

The global NICU genetic testing market is forecast to grow from USD 1.74 billion in 2026 to USD 4.80 billion by 2036, at a 10.67% CAGR. Growth is driven by rising neonatal genetic disorders, rapid whole genome and exome sequencing, next-generation sequencing, chromosomal microarrays and personalized neonatal care. North America leads the market, while Asia-Pacific is expected to grow fastest. The report analyzes key trends, technologies, segments, regional opportunities and leading companies, in

Yahoo · Sep 20, 2026

Illumina Stock Is Up 133% This Year. Here’s Where It Could Go Further.

Key TakeawaysYear-Long Surge: Illumina stock has climbed 133% over the past year, closing at $240 on September 18, 2026, up from roughly $103 twelve months earlier. Street Split: Illumina stock carries 7 buy ratings, 4 outperforms, 6 holds, 3 underperforms and 1 sell, and the $203 mean target now sits 15% below where shares trade, a reversal from a year ago when the target sat above the price.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By